Eslicarbazepine use in Multiple Sclerosis with refractory trigeminal neuralgia

Posted in Case Reports on 15th Mar 2013

Author

Tarek Gaber et al

Dr Tarek A-Z K Gaber, FRCP (London), Consultant in Neurological Rehabilitation, Wrightington, Wigan and Leigh NHS Foundation Trust, UK
Dr Myint Myint Kyu, MRCP (UK), Specialist Registrar in Rehabilitation Medicine, North West of England Deanery, UK
Dr Wah Wah Oo, MRCP (UK), Specialist Registrar in Rehabilitation Medicine, North West of England Deanery, UK

Correspondence to:
Dr Tarek Gaber, Consultant in Neurological Rehabilitation, Leigh Infirmary, Leigh, Lancs. UK WN7 3NF Tel 01942 264078, Fax 01942 264517
Email: Tarek Gaber

Competing interest: The first author was a member of the Central Region Faculty for Jovin Healthcare the manufacturers of Eslicarbazepiune (Zebinex). He was paid an honorarium for his membership

First published online at BJMP 2013;6(1):a602

When associated with Multiple Sclerosis (MS), Trigeminal Neuralgia (TN) is often bilateral and more refractory to treatment. carbamazepine is the first line of treatment for TN, however, common side effects of carbamazepine such as hyponatremia occasionally limit its use.

We report the case of a 62 year old female patient with a well controlled MS associated TN using carbamazepine. This drug needed to be discontinued because of recurrent symptomatic hyponatremia. Several agents including topiramate, gabapentin and amitriptyline were tried but none had any beneficial effect on TN. A small dose of eslicarbazepine (400 mg daily) provided excellent control of the TN pain on one hand and did not affect the plasma sodium levels on the other hand.

Eslicarbazepine main advantage is providing the same effects of carbamazepine or oxcarbazepine but with an incidence of hyponatremia of less than 1%, it is much safer to use when the risk of hyponatremia is increased. To our knowledge, this is the first case that reports the use of eslicarbazepine in one of the several indications of carbamazepine such as pain and mental health problems. Eslicarbazepine use in epilepsy was reported extensively.

We feel that a therapeutic trial of eslicarbazepine is justified when either carbamazepine or oxcarbazepine have to be discontinued because of hyponatremia despite their efficacy.

Introduction

Trigeminal Neuralgia (TN) is relatively rare in Multiple Sclerosis (MS) affecting approximately 2% of patients1. The severity of the pain is indistinguishable whether TN is an isolated impairment or is associated with MS. However, when associated with MS, TN is often bilateral, affecting younger patients and is more refractory to medical treatment2.

Several pharmacological agents are reported to be effective in TN associated with MS. Topiramate3,4, gabapentin5 and lamotrigine6 were all reported to benefit patients with TN associated with MS in small uncontrolled trials. Several other drugs such as phenytoin, misoprostol and amitriptyline are routinely tried in patients with TN despite the lack of convincing evidence of efficacy7.

In 2008, both The American Academy of Neurology and the European Federation of Neurological Societies launched a joint task force to prepare general guidelines for the management of TN. After systematic review of the literature the task force came to a series of evidence-based recommendations. carbamazepine and oxcarbazepine had the strongest evidence of efficacy and were recommended as first line treatment8. An earlier Cochrane systematic review reached the same conclusion9.

Case report

A 62 year old female patient had been suffering from MS for about 20 years. The MS presented with trigeminal neuralgia from the outset and this was then followed by pyramidal lower limbs’ weakness and sphincteric dysfunction. The patient started to use a wheelchair 10 years ago but she became totally wheelchair dependent about 6 years later.

Trigeminal neuralgia remained active throughout the 20 years. carbamazepine (300 mg daily) provided the patient with a satisfactory control of TN. Despite having occasional break through TN pain, the patient declined having higher doses of carbamazepine as excessive sedation was an unacceptable side effect.

In the last year, the patient was admitted to hospital in two separate occasions complaining of increasing malaise and confusion. Plasma sodium levels were found to be low in both occasions (first presentation 118 mmol/l and second admission 114 mmol/l). Clinical evaluation confirmed Syndrome of Anti Diuretic Hormone Secretion (SIADH) as the cause of the hyponatremia and in the absence of any other explanation for the SIADH; carbamazepine was thought to be the main reason and was duly discontinued.

Unfortunately her attacks of TN came back with vengeance. During the following 6 months, therapeutic trials using gabapentin, topiramate and amitriptyline failed to show any beneficial effect on either the severity or the frequency of the TN attacks. All three drugs were duly discontinued.

The patient was started on eslicrbazepine 400 mg as a single daily dose. This dose lead to almost complete eradication of the TN attacks. The control of TN and the plasma sodium levels remained stable 6 months following the initiation of the therapy.

Comments

Hyponatremia, defined as a sodium level < 135 mmol/l is a common side effect of carbamazepine and oxcarbazepine therapy. The incidence of hyponatremia secondary to carbamazepine therapy ranges between 4.8 and 40% depending on the population studied10,11. In most cases, hyponatremia is asymptomatic and continuation of the carbamazepine use is possible whilst a close eye is kept on the plasma sodium level10. In rare occasions hyponatremia is symptomatic and discontinuation of carbamazepine is warranted. Administration of demeclocycline to normalise the sodium level was suggested by some authors12 However, the long term use of demeclocycline is associated with several complications and this approach is hardly a standard practice.

Clinicians often face a dilemma when carbamazepine is the only agent able to control a specific clinical problem. With many antiepileptics available, it is unusual to face such a problem in epileptic patients. Trigeminal neuralgia on the other hand can be extremely difficult to control and carbamazepine was found to have a unique ability to manage such unpleasant condition even before its antiepileptic effects were noticed on 196213.

Eslicarbazepine is promoted as an alternative to carbamazepine when side effects occurs on otherwise responsive patients to its favourable antiepileptic effects14. Hyponatremia is rare in eslacarbazepine users with only an incidence of less than 1% in the small populations studied15,16.  Frequency of hyponatraemia increased with increasing eslicarbazepine dose. In patients with pre-existing renal disease leading to hyponatraemia, or in patients concomitantly treated with medicinal products which may themselves lead to hyponatraemia17.

Our patient showed the same favourable response to eslicarbazepine as she experienced with carbamazepine. However, Hyponatremia did not occur with eslicarbazepine therapy. This enabled our patient to continue with pharmacological management and avoid surgical interventions.

With the exception of epilepsy, No reports are available commenting on the use of eslicarbazepine on the wide range of conditions that carbamazepine is traditionally used for such as mental health problems or pain. When patients are well controlled on carbamazepine whatever the indication is, the occurrence of side effects such as hyponatremia is often managed by an automatic replacement with another agent. We feel that in such patients a therapeutic trial of eslacarbazepine might be appropriate especially if the control on carbamazepine was robust or if the benefits of carbamazepine therapy were clearly superior to other pharmacological agents potentially useful for the targeted clinical condition.

References

1- Hooge JP, Redekop WK. Trigeminal Neuralgia in Multiple Sclerosis. Neurology 1995; 45(7):1294-6.

2- Brisman R. Trigeminal neuralgia and Multiple Sclerosis. Arch Neurol. 1987;44(4):379-381.

3- Zvartau-Hind MDin MUGilani ALisak RPKhan OA. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology 2000; 55(10):1587-8.

4- Gilron IBooher SLRowan JSMax MB. Topiramate in trigeminal neuralgia: a randomized, placebo-controlled multiple crossover pilot study. Clin Neuropharmacol. 2001; 24(2):109-12

5- Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998; 51(2):611-4.

6- Leandri MLundardi GInglese MMessmer-Uccelli MMancardi GLGottlieb ASolaro C. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol 2000; 247(7):556-8.

7-Cheng JSSanchez-Mejia ROLimbo MWard MMBarbaro NM. Management of medically refractory trigeminal neuralgia in patients with multiple sclerosis. Neurosurg Focus 2005; 18(5):e13.

8-  Gronseth GCruccu GArgoff CBrainin MBurchiel KNurmikko TZakrzewska JMAmerican Academy of Neurology SocietyEuropean Federation of Neurological Society. AAN-EFNS guidelines on trigeminal neuralgia management. Eur J Neurol. 2008 Oct;15(10):1013-28.

9- Wiffen PMcQuay HCarroll DJadad AMoore A. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2000;(2):CD001133.

10- Dong X, Leppik IE, White J, Rarick J. Hyponatremia from Oxcarbazepine and carbamazepine. Neurology 2005; 65(12): 1976-1978

11- Van Amelsvoort TH, Bakshi R, Devaux CB, Schwabe S. Hyponatremia Associated with carbamazepine and Oxcarbazepine Therapy: A Review. Epilepsia 1994; 35(1): 181-188

12- Brewerton TD, Jackson CW. Prophylaxis of carbamazepine-induced hyponatremia by demeclocycline in six patients. The Journal of Clinical Psychiatry 1994; 55(6): 249-251

13- Schindler W, Häfliger F. Über Derivate des IminodibenzylHelvetica Chimica Acta 1954; 37 (2): 472–83.

14- Elger C et al Efficacy & Safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomised, double-blind, placebo-controlled, parallel group, phase III study, Epilepsia, 2009; 50; (3): 453-63

15- Versavel M et al, An investigation of the effects of eslicarbazepine acetate on hyponatraemia: A pooled analysis of three double-blind phase III clinical studies. Poster presented AES Annual Meeting Dec 2009, San Antonio

16- Nunes T et al. Incidence of rash and hyponatraemia in adult patients with refractory partial seizures treated with adjunctive eslicarbazepine acetate: Results from three phase III studies and 1-year open-label extensions. Poster presented at ECE Annual Meeting June 2010, Rhodes.

17- Gil-Nagel A et al, Efficacy and safety of 800 mg and 1200 mg eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures, Acta Neurol Scand, 2009; 120: 281-287.

SIGN UP FOR OUR MAILING LIST

Open Access, for medical professionals: Sign up to receive our email newsletter with links to the latest content. ACNR is free, thanks to the support of advertisers. The editorial content is peer reviewed and remains completely independent unless clearly specified. 

We may infrequently send you news from our sponsors which is relevant to the field of neurology, but you can opt out at any time.

See a sample email newsletter here
This website is for medical professionals only.